See more : Viavi Solutions Inc. (VIAV) Income Statement Analysis – Financial Results
Complete financial analysis of Ono Pharmaceutical Co., Ltd. (4528.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ono Pharmaceutical Co., Ltd., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- Hargreaves Services Plc (HSP.L) Income Statement Analysis – Financial Results
- KWG Living Group Holdings Limited (KWLGF) Income Statement Analysis – Financial Results
- ING Groep N.V. (INGVF) Income Statement Analysis – Financial Results
- Swire Properties Limited (SWPFF) Income Statement Analysis – Financial Results
- Affluent Foundation Holdings Limited (1757.HK) Income Statement Analysis – Financial Results
Ono Pharmaceutical Co., Ltd. (4528.T)
About Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 502.67B | 447.19B | 361.36B | 309.28B | 292.42B | 288.63B | 261.84B | 244.80B | 160.28B | 135.78B | 143.25B | 145.39B | 145.78B | 135.26B | 135.99B | 136.56B | 145.90B | 141.71B | 148.67B | 145.30B |
| Cost of Revenue | 127.13B | 110.06B | 93.51B | 85.57B | 79.06B | 83.83B | 65.39B | 65.52B | 41.52B | 35.14B | 32.75B | 33.98B | 28.99B | 24.76B | 20.84B | 21.32B | 20.86B | 21.09B | 21.82B | 21.01B |
| Gross Profit | 375.55B | 337.13B | 267.85B | 223.71B | 213.36B | 204.81B | 196.45B | 179.27B | 118.76B | 100.64B | 110.50B | 111.41B | 116.79B | 110.50B | 115.15B | 115.24B | 125.04B | 120.63B | 126.86B | 124.29B |
| Gross Profit Ratio | 74.71% | 75.39% | 74.12% | 72.33% | 72.96% | 70.96% | 75.03% | 73.23% | 74.09% | 74.12% | 77.14% | 76.63% | 80.12% | 81.69% | 84.68% | 84.39% | 85.70% | 85.12% | 85.33% | 85.54% |
| Research & Development | 112.17B | 95.34B | 75.88B | 62.38B | 66.50B | 70.01B | 68.82B | 57.51B | 43.37B | 41.35B | 44.41B | 45.44B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 100.27B | 89.49B | 77.06B | 69.23B | 67.68B | 70.03B | 68.06B | 62.05B | 43.98B | 42.22B | 38.38B | 70.80B | 67.49B | 65.24B | 64.75B | 62.93B | 61.79B | 57.88B | 58.17B | 53.39B |
| Selling & Marketing | 0.00 | 17.84B | 11.50B | 6.90B | 5.78B | 4.72B | 3.71B | 2.88B | 1.29B | 1.10B | 964.00M | 8.69B | 11.39B | 10.05B | 10.55B | 8.83B | 10.96B | 9.90B | 11.75B | 10.85B |
| SG&A | 100.27B | 89.49B | 77.06B | 69.23B | 67.68B | 70.03B | 68.06B | 62.05B | 43.98B | 42.22B | 38.38B | 79.49B | 78.89B | 75.30B | 75.31B | 71.77B | 72.75B | 67.78B | 69.92B | 64.24B |
| Other Expenses | -1.00M | 0.00 | 11.72B | -6.23B | 1.69B | 2.75B | -1.12B | -12.57B | 904.00M | 2.28B | 1.28B | -537.00M | 1.36B | 942.00M | 1.35B | 1.60B | 1.30B | 2.63B | 1.46B | 1.18B |
| Operating Expenses | 212.44B | 195.16B | 164.65B | 125.38B | 135.87B | 142.80B | 135.76B | 106.99B | 88.25B | 85.85B | 84.08B | 79.49B | 78.89B | 75.30B | 75.31B | 71.77B | 72.75B | 67.78B | 69.92B | 64.24B |
| Cost & Expenses | 339.57B | 305.22B | 258.17B | 210.95B | 214.93B | 226.62B | 201.15B | 172.51B | 129.78B | 120.98B | 116.82B | 113.47B | 107.87B | 100.05B | 96.14B | 93.08B | 93.61B | 88.87B | 91.73B | 85.26B |
| Interest Income | 4.03B | 2.48B | 2.71B | 2.69B | 3.05B | 3.28B | 3.28B | 3.06B | 3.09B | 3.57B | 3.11B | 788.00M | 1.09B | 1.33B | 1.47B | 1.67B | 1.57B | 1.19B | 737.00M | 741.00M |
| Interest Expense | 229.00M | 913.00M | 874.00M | 137.00M | 845.00M | 150.00M | 36.00M | 260.00M | 291.00M | 67.00M | 76.00M | 2.00M | 0.00 | 0.00 | 0.00 | 0.00 | 1.00M | 0.00 | 1.00M | 3.00M |
| Depreciation & Amortization | 18.14B | 17.45B | 17.72B | 15.82B | 14.21B | 10.62B | 9.21B | 7.82B | 6.53B | 6.10B | 5.11B | 2.85B | 3.01B | 3.05B | 3.01B | 3.00B | 3.38B | 3.52B | 4.03B | 4.22B |
| EBITDA | 181.98B | 167.50B | 128.54B | 114.54B | 94.00B | 74.20B | 67.39B | 83.92B | 36.89B | 21.78B | 31.66B | 37.73B | 43.01B | 39.95B | 46.15B | 43.28B | 62.90B | 65.12B | 63.77B | 70.02B |
| EBITDA Ratio | 36.20% | 36.20% | 34.21% | 37.78% | 32.40% | 26.30% | 27.95% | 33.75% | 25.02% | 18.02% | 24.18% | 25.34% | 29.81% | 30.01% | 33.62% | 36.44% | 40.09% | 42.43% | 42.57% | 45.64% |
| Operating Income | 163.10B | 141.96B | 103.20B | 98.33B | 77.49B | 62.01B | 60.68B | 72.28B | 30.51B | 14.79B | 26.42B | 31.92B | 37.90B | 35.20B | 39.84B | 43.47B | 52.29B | 52.84B | 56.94B | 60.04B |
| Operating Income Ratio | 32.45% | 31.75% | 28.56% | 31.79% | 26.50% | 21.48% | 23.18% | 29.53% | 19.03% | 10.90% | 18.45% | 21.95% | 26.00% | 26.02% | 29.30% | 31.83% | 35.84% | 37.29% | 38.30% | 41.32% |
| Total Other Income/Expenses | 630.00M | 1.57B | 1.83B | 2.56B | 516.00M | 377.00M | 3.24B | 2.26B | 2.77B | 3.51B | 3.03B | 1.08B | 2.11B | 1.70B | 3.30B | -3.20B | 7.23B | 8.75B | 2.81B | 5.75B |
| Income Before Tax | 163.73B | 143.53B | 105.03B | 100.89B | 79.70B | 65.14B | 63.92B | 74.54B | 33.27B | 18.31B | 29.46B | 34.66B | 40.01B | 36.90B | 43.14B | 40.27B | 59.51B | 61.60B | 59.75B | 65.79B |
| Income Before Tax Ratio | 32.57% | 32.10% | 29.06% | 32.62% | 27.25% | 22.57% | 24.41% | 30.45% | 20.76% | 13.48% | 20.56% | 23.84% | 27.45% | 27.28% | 31.73% | 29.49% | 40.79% | 43.47% | 40.19% | 45.28% |
| Income Tax Expense | 35.69B | 30.62B | 24.34B | 25.39B | 19.81B | 13.46B | 13.53B | 18.50B | 8.08B | 5.09B | 8.91B | 10.32B | 15.38B | 12.42B | 15.06B | 16.27B | 24.04B | 26.01B | 23.31B | 26.25B |
| Net Income | 127.98B | 112.72B | 80.52B | 75.43B | 59.70B | 51.54B | 50.28B | 55.79B | 24.98B | 12.98B | 20.35B | 24.12B | 24.36B | 24.22B | 27.88B | 23.77B | 35.05B | 35.27B | 36.15B | 39.32B |
| Net Income Ratio | 25.46% | 25.21% | 22.28% | 24.39% | 20.42% | 17.86% | 19.20% | 22.79% | 15.58% | 9.56% | 14.21% | 16.59% | 16.71% | 17.91% | 20.50% | 17.40% | 24.02% | 24.89% | 24.31% | 27.06% |
| EPS | 266.61 | 230.85 | 162.19 | 151.11 | 118.47 | 100.25 | 97.00 | 105.27 | 47.13 | 4.90 | 7.68 | 43.24 | 45.96 | 44.78 | 51.28 | 43.22 | 61.37 | 60.55 | 61.47 | 66.81 |
| EPS Diluted | 266.60 | 230.79 | 162.16 | 151.09 | 118.45 | 100.24 | 96.99 | 105.26 | 47.13 | 4.90 | 7.68 | 43.24 | 45.96 | 44.78 | 51.28 | 43.22 | 12.79 | 60.55 | 61.47 | 66.81 |
| Weighted Avg Shares Out | 480.01M | 488.30M | 496.46M | 499.14M | 503.98M | 514.12M | 518.39M | 530.02M | 530.03M | 530.00M | 530.02M | 530.03M | 530.04M | 530.04M | 530.04M | 530.04M | 530.04M | 530.04M | 530.04M | 530.04M |
| Weighted Avg Shares Out (Dil) | 480.04M | 488.35M | 496.53M | 499.20M | 504.04M | 514.17M | 518.43M | 530.04M | 530.04M | 530.00M | 530.02M | 530.03M | 530.04M | 530.04M | 530.04M | 530.04M | 530.04M | 530.04M | 530.04M | 530.04M |
Source: https://incomestatements.info
Category: Stock Reports